INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) is renewing investor interest in its biosynthesis technology that has the potential to address regulatory concerns associated with pharmaceutical grade cannabinoids.

The biosynthesis technology should allow the company to produce high yield cannabinoids for its pipeline, rather than having to outsource cultivation, as is the case with other cannabis-focused biotech’s. IMLFF will be using this technology to deliver CBD oils through a hydrogel and are making moves to mass-produce this product.

IMLFF’s technology has the potential to give rise to commercial quantities of cannabinoids without the normal production and maintenance costs pitfalls. IMLFF has managed to bounce back after coming under pressure after rising to $0.66 a share in April. The stock is up by more than 100% for the year as it continues to make a surge for its 52-week high.

INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) casts itself as a biopharmaceutical company specializing in developing cannabis-based therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

IMLFF is utilizing its proprietary Intelligent Cannabinoid Drug Design Platform to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific diseases.

The big picture is that this is a pre-clinical stage biopharmaceutical company specializing in the research, development, and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs. The Company has three core assets: a proprietary Bioinformatics assessment tool to match individual (or combination of) cannabinoids against disease targets; a proprietary Biosynthesis cannabinoid manufacturing system to economically produce all 90+ cannabinoids at pharmaceutical-grade (>99.5% purity); and drug development program enabled by the two aforementioned tools. Leaders in the pipeline include a treatment for the symptoms and, potentially, the underlying disease in Epidermolysis Bullosa, a rare, devastating genetic skin disorder; and, a once-a-day eyedrops formulation of cannabinoids to treat Glaucoma, one of the leading causes of blindness in the developed world.

According to company materials, “InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.”

Find out when $IMLFF reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

In other news, IMLFF has appointed, Dr. Mauro Maccarrone, to its scientific advisory board. Dr. Maccarrone currently serves as the Professor and Chair of Biochemistry and Molecular Biology at the University of Rome.

We are very pleased to add Dr. Mauro Maccarrone and his vast experience in the field of cannabinoid research as an integral part of our Scientific Advisory Board. We look forward to working with Dr. Maccarrone to help bring drug therapies to those in need,” said Dr. Sazzad Hossain, InMed’s Chief Scientific Officer

Earning a current market cap value of $25.33M, IMLFF has a significant war chest ($6.7M) of cash on the books. IMLFF is renewing interest and the stock has been rebounding. We will be following this story. Sign-up for continuing coverage on shares of $IMLFF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $IMLFF, either long or short, and we have not been compensated for this article.